Novartis Ag (NVS) Treasury Shares (2009 - 2026)
Novartis Ag (NVS) posted Treasury Shares of $49.0 million for Q2 2026, up 204.26% sequentially from -$47.0 million in Q1 2026, and up 248.48% YoY from $14.1 million in Q2 2025.
Novartis Ag (NVS) Treasury Shares (2009 - 2026) Analysis & Trends
Novartis Ag has reported Treasury Shares for 18 years, with the latest figure at $49.0 million in Q2 2026.
- Quarterly Treasury Shares rose 248.48% year-over-year to $49.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $49.0 million (up 248.48% YoY) and the FY2025 annual result came in at $50.0 million, up 194.34% from the prior year.
- Treasury Shares climbed to $49.0 million in Q2 2026 per NVS's latest filing, from -$47.0 million in the prior quarter.
- Over five years, Treasury Shares peaked at -$3.0 million in Q4 2019 and troughed at -$5.3 billion in Q2 2022.
- A 4-year average of -$1.2 billion and a median of -$253.0 million in 2019 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2026: Treasury Shares plunged 229.27% in 2024, then surged 248.48% in 2026.
- Over 5 years, Treasury Shares stood at $92.0 million in 2022, then slumped by 55.43% to $41.0 million in 2023, then slumped by 229.27% to -$53.0 million in 2024, then soared by 194.34% to $50.0 million in 2025, then slipped by 2.0% to $49.0 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $49.0 million, -$47.0 million, and $50.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.08 Bn | 633.32 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 470.80 Bn | 464.23 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 377.96 Bn | 370.82 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.49 Bn | 295.80 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.97 Bn | 253.07 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.98 Bn | 222.99 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.41 Bn | 179.23 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.08 Bn | 47.70 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.00 Mn |
| Jun 30, 2026 | 49.00 Mn |
| Mar 31, 2026 | -47.00 Mn |
| Mar 31, 2026 | -47.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Sep 30, 2025 | -44.00 Mn |
| Sep 30, 2025 | -44.00 Mn |
| Jun 30, 2025 | -33.00 Mn |
| Jun 30, 2025 | -33.00 Mn |
| Mar 31, 2025 | -19.00 Mn |
| Mar 31, 2025 | -19.00 Mn |
| Dec 31, 2024 | -53.00 Mn |
| Dec 31, 2024 | -53.00 Mn |
| Sep 30, 2024 | -40.00 Mn |
| Sep 30, 2024 | -40.00 Mn |
| Jun 30, 2024 | -25.00 Mn |
| Jun 30, 2024 | -25.00 Mn |
| Mar 31, 2024 | -17.00 Mn |
| Mar 31, 2024 | -17.00 Mn |